Terms of Service

The Service is supplied by ResPublica Intelligence LTD (Company Number SC893159), trading as PharmAnalyser (“we”, “us”, “our”). We are registered in Scotland.

2.1 Registered office

Our registered office is 32 St. Andrews Road, Glasgow, Scotland, G41 1PF, United Kingdom.

2.2 Contact

Legal and operational enquiries: support@pharmanalyser.co.uk.

In these Terms:

• Account: your registered profile on the main application (pharmanalyser.co.uk).
• Enterprise workspace: contract-led access on app.pharmanalyser.co.uk.
• Checkout: the online purchase flow for subscriptions or Reports.
• Content: our software, user interface, documentation, layouts, and proprietary presentation, excluding Source data except as licensed.
• Derived output: metrics, ranks, matches, scores, commentary, charts, map layers, or Report sections we calculate or compose from Source data and rules.
• Main-app plans: Free, Plus, Pro, and add-on modules sold through standard Checkout unless stated otherwise.
• Report: a generated pharmacy or GP analytics document (PDF, web view, or export) you purchase or generate under entitlement.
• Source data: third-party and public datasets (including NHS and regulatory publications) we obtain for analytics.
• Snapshot: the Source data and Derived output fixed at Report generation time.
• User content: labels, notes, watchlist metadata, and similar inputs you provide.

4.1 Subscriptions

When you complete Checkout for a subscription, you make an offer on the plan, price, and billing interval shown. We accept when payment succeeds and we enable access (or when we send an order confirmation, if earlier).

4.2 Reports

When you order a Report, you make an offer for the organisation, template, and sections shown before payment. We accept when payment succeeds and we start generation, or when we confirm the order in writing, if earlier.

4.3 Entitlement Reports

If a Report is included in your plan without separate payment, acceptance occurs when you submit the generation request and we queue the job.

4.4 Errors

Obvious pricing or description errors may be corrected before acceptance. Where permitted by law, we may cancel an affected order and refund you.

PharmAnalyser provides organisation-level analytics for UK pharmacies, GP practices, and related geographies. Features vary by nation, plan, Enterprise entitlements, and product area.

5.1 Not clinical care

The Service is not a medical device, clinical decision support system, or substitute for professional healthcare advice. Do not use it to identify, contact, or profile individual patients.

5.2 Changes to the Service

We may modify features, interfaces, or data coverage. We will give reasonable notice of material adverse changes to paid features where required by law or your plan terms.

You must provide accurate registration details and keep credentials confidential. You are responsible for activity under your Account unless caused by our failure to maintain reasonable security.

6.1 Age and capacity

You must be at least 18 and able to enter a binding contract.

6.2 Organisation accounts

Organisation administrators may invite users and configure roles where the product allows. Administrators are responsible for ensuring invited users comply with these Terms and for revoking access when appropriate.

6.3 Enterprise administration

Enterprise administrators may assign roles and limits under the Enterprise agreement. We apply the settings they configure.

6.4 Security incidents

Notify support@pharmanalyser.co.uk promptly if you suspect unauthorised access.

If you are a consumer (an individual acting for purposes wholly or mainly outside your trade, business, craft, or profession), mandatory UK consumer protections apply and cannot be excluded where the law forbids it.

7.1 Business use

If you register a business Account or use the Service primarily for commercial purposes, sections on indemnities and certain liability limitations apply as stated, subject always to mandatory consumer rules where you remain a consumer. Choosing a business account type at registration does not by itself prove you are not a consumer if your use is otherwise personal.

7.2 Professional firms

Consultants, brokers, and advisers using the Service for client work remain responsible to their clients and must comply with section 14 and section 22.

Plan features and limits are those shown on our pricing pages and at Checkout when you subscribe.

8.1 Free tier

Free access may be feature-limited and may change with notice where required.

8.2 Paid tiers

Plus and Pro include modules described at purchase. Some capabilities require both tier and module entitlements.

Enterprise access is provided under a separate Enterprise agreement and app.pharmanalyser.co.uk. Main-app Checkout does not create Enterprise rights unless expressly stated in writing.

9.1 Precedence

On matters within its scope (fees, seats, permitted use, service levels, liability, and data processing), the Enterprise agreement prevails over these Terms for that workspace.

Main-app subscriptions are billed through our payment provider unless we agree otherwise. Prices, intervals, and taxes are shown at Checkout and in the billing portal.

10.1 Automatic renewal

Subscriptions renew for the same interval until you cancel before the renewal date shown in the portal.

10.2 Failed payment

We may retry charges and restrict access after reasonable notice where permitted by law.

10.3 Enterprise

Enterprise invoicing follows the Enterprise agreement.

This section applies alongside your statutory rights under the Consumer Rights Act 2015 (CRA) and, where relevant, the Consumer Contracts (Information, Cancellation and Additional Charges) Regulations 2013 (CCRs). Nothing here limits those rights.

11.1 Types of contract

Different rules apply depending on what you buy. A recurring subscription is mainly a contract for ongoing digital services. A separately purchased Report is mainly a contract for digital content supplied once. Do not assume the same cancellation rules apply to both.

11.2 Cancelling subscription renewals

You may cancel future subscription renewals via billing settings or the customer portal. Cancellation stops future charges; access usually continues until the end of the current paid period unless we state otherwise.

11.3 Consumer cancellation — ongoing services (CCRs regulations 29–37)

If you are a consumer and you enter a distance contract for digital services supplied on a continuing basis, you may have a 14-day right to cancel from the day after the contract is formed. That right is separate from rules about digital content supplied as a single download or generation.

11.4 Early performance of services and loss of cancellation rights

If you are a consumer and you ask us to begin supplying the subscription service during the cancellation period, you may lose the right to cancel once the service has been fully performed. If you cancel after partial performance, you may owe a proportionate amount for the service supplied up to cancellation, calculated in line with the CCRs where they apply.

11.5 Consumer cancellation — digital content (Reports and similar)

If you are a consumer and you buy a Report or other digital content not supplied on a tangible medium, the CCRs may allow you to lose the 14-day cancellation right only if: (a) you expressly consent to us beginning supply during the cancellation period; (b) you acknowledge that you will lose the right to cancel once supply begins; and (c) we provide that information and confirmation as the regulations require. We will only rely on such loss of rights where those conditions are met at the time of purchase.

11.6 CRA remedies for digital content (including section 47)

Digital content (including a Report) must be of satisfactory quality, fit for a particular purpose made known to us, and as described. If it is not, you may have remedies under the CRA including repair, replacement, price reduction, or in serious cases a refund, whether or not you downloaded the file.

11.7 CRA remedies for services (including section 57)

If the subscription service is not performed with reasonable care and skill or as agreed, you may have remedies under the CRA including repeat performance or, if that is impossible or not done within a reasonable time, a price reduction or refund for the affected period.

11.8 Report refunds

Report-specific delivery and refund commitments are in section 13. A Report is not automatically non-refundable merely because generation completed or a file was downloaded if the deliverable is faulty or not as described.

11.9 Business purchasers

If you are not a consumer, refund rights are limited to these Terms, terms shown at purchase, and applicable law.

11.10 Statutory reimbursement timing (CCRs regulation 34)

Where the CCRs require us to reimburse you following a valid cancellation, we will make that reimbursement within fourteen days starting from the day we receive your cancellation notice, using the same payment method unless you agree otherwise. This timing applies to statutory cancellation refunds, not to every goodwill or discretionary refund we may offer.

11.11 Other refunds and timing

Refunds under the CRA or under section 13 follow those provisions. Other approved refunds are returned to the original payment method where possible within a reasonable period.

Watchlists and saved views help you track organisations. Limits depend on your plan or Enterprise contract.

12.1 Alerts

Alerts depend on data refresh schedules and delivery channels. We do not guarantee detection of every source-data change.

12.2 User content licence

You grant us a licence to host User content solely to operate the Service. You must have rights to any content you upload.

Reports are organisation-level analytics documents. They support commercial research and advisory work subject to these Terms—they are not audited financial statements, certified accounts, or regulated investment advice.

13.1 Ordering

Before payment you select the target organisation, Report type, data edition, and sections shown in the product. You are responsible for verifying codes, region, and organisation identity before purchase.

13.2 Generation

1. Payment or plan entitlement is confirmed.
2. Generation is queued using Source data available at that time.
3. Automated checks run; we do not manually audit every figure.
4. The Report is made available in your Account (download and/or web view). You may enable a share link if the product allows.

13.2a Selected sections (material delivery)

When you purchase or generate a Report, the sections you select at checkout or in the generation request (shown in the product before you commit) form part of what we must deliver in usable form. A section is delivered in usable form when it appears in the Report with the substantive analytics or narrative content described for that section at purchase, except where we clearly disclose in the Report that a particular field or sub-component is unavailable for that organisation, edition, or nation without treating the whole purchased section as undelivered.

Minor gaps, rounding, or disclosed limitations in non-purchased sections, footnotes, or optional context do not by themselves mean we failed to deliver a purchased section. We do not guarantee that every underlying Source contains complete information for every organisation, period, or metric.

13.3 Delivery timing

Any stated delivery time is an estimate. Generation may fail because of upstream data gaps, timeouts, or load. Where the product offers retry, you may use it for eligible failures.

13.4 Snapshots

A Report reflects a Snapshot. Official publishers may later revise or withdraw data. A Report does not automatically update when sources change.

13.5 Accuracy limits

Reports may contain errors from Source data, location matching, organisation matching, statistical methods, or narrative text. See sections 17–20.

13.6 Delays, retries, and temporary unavailability

Generation may be delayed while we wait for Source data, complete retries, or recover from load. A delay is not the same as non-delivery. Where the product offers retry, you may use it for eligible failures while the job remains open, including failures affecting a purchased section we treat as material to delivery.

13.7 Permanent non-delivery and remedies

If, after reasonable retries, we determine the Report cannot be delivered in usable form for one or more purchased sections (including because required Source data remains unavailable or generation fails terminally), we apply the remedies below. This applies whether the underlying cause is within our systems or upstream publishers—we do not charge you for a Report you never receive in usable form for the sections you purchased. This section does not extend to consequential or indirect losses, and does not apply where non-delivery is caused by your error (such as selecting the wrong organisation or region when other choices were shown). Nothing in this section limits remedies that cannot be excluded under mandatory consumer law.

13.7a Separate payment (monetary refund)

If you paid a separate fee for the Report at checkout, we refund that Report fee for the affected purchase once we determine terminal non-delivery under section 13.7. We do not double-refund once a refund or charge reversal for that Report is recorded.

13.7b Included or entitlement-funded Reports

If the Report was funded only from an included allowance, plan entitlement, or enterprise credit without a separate payment at checkout, we restore equivalent entitlement (such as a report credit or allowance unit) instead of a monetary refund where section 13.7 applies.

13.8 Faulty or misdescribed Reports

If you are a consumer and a Report does not meet the CRA standard in section 11.6, your statutory remedies apply. If you are a business customer, contact us with details; we will consider re-generation or refund where appropriate and consistent with these Terms.

13.9 Valuation and investment

Reports are not audited valuations, lending approvals, or investment recommendations. Financial sections interpret published data; they do not guarantee future income or enterprise value.

13.10 Verification

You should verify material figures against primary publisher records and obtain appropriate professional advice before lending, acquisition, pricing, or regulatory decisions.

13.11 Retention after cancellation

Stored Reports and share links remain available according to your plan, product retention settings, and these Terms. We may delete stored Reports after account closure where the Privacy Policy and law allow.

Subject to payment and these Terms, we grant a non-exclusive, non-transferable licence to use Reports as described below.

14.1 Internal use

You may use Reports internally for research, operations, and decision support within your organisation.

14.2 Professional and commercial use (extracts)

You may include appropriately attributed excerpts, summary statistics, charts, or stated conclusions from a Report in client advisory reports, broker packs, lending submissions, investor presentations, acquisition assessments, and similar internal or client-specific materials, provided you:

• Identify PharmAnalyser and the Report date (and organisation where relevant).
• Do not publish or resell the full Report or substantially all sections as a standalone product or data feed.
• Do not remove disclaimers, attribution, or copyright notices from excerpts.
• Do not imply NHS, GPhC, or regulator endorsement.
• Comply with section 17 when reusing Source data within permitted extracts.

14.3 Shared Report web copy (authentication and access)

Where the product provides a share link for a Report web copy, recipients must be registered PharmAnalyser users and must sign in to view or download that Report. A Free Account is sufficient to open a valid shared link; we do not require a paid Plus or Pro subscription merely to access a link you were invited to view. Signing in does not grant access to your Account, your other Reports, or your billing.

The link uses an unguessable token in the URL. Share invitation emails we send contain the web link only—not an unrestricted PDF attachment—when the product is configured for link-only sharing. You may give a link to clients, lenders, or advisers you trust to view that Report. This is not permission to rehost the Report on a public website, resell access, or redistribute bulk data extracted from it.

14.3a Expiry, revocation, and discovery

New report-sharing links expire 30 days after they are created by default. This default does not retrospectively alter report-sharing links created before the policy takes effect. A link may be revoked earlier where that functionality is available. We intend shared Report pages not to be indexed by conventional search engines, but noindex settings are not a guarantee of absolute secrecy. Forwarding, screenshots, or copies outside our service remain your responsibility.

Revocation and expiry stop new access through our service; they do not recall files already downloaded or copied outside PharmAnalyser. Links issued before a product change may continue under earlier settings until replaced or revoked; we do not promise that every historic link will remain valid indefinitely.

14.4 Prohibited uses

You must not:

• Resell, sublicense, or publish Reports (or substantial parts) as a commercial publication or dataset without our written consent.
• Use share links to circumvent subscription, Enterprise, or Report paywalls for unrelated organisations.
• Replicate or rebuild our analytical database or systematic Derived output outside permitted product features.
• Present Reports or extracts as official NHS or regulator documents.

14.5 Dataset-specific limits

Some Source data in a Report may be subject to publisher conditions. Where we show those conditions in the product, in section 17, or in the Report, they apply to your reuse (including permitted extracts). If we have not disclosed a restriction that applies to you, we will not rely on it to penalise use that section 14.2 otherwise allows.

We own or license Content and the Service. Source data remains subject to publisher rights.

15.1 Service licence

While your Account is in good standing, we grant a limited, revocable licence to access the Service according to your plan.

15.2 Feedback

Feedback may be used to improve the Service without obligation to you.

You must not:

• Scrape, bulk export, or systematically harvest Source data or Derived output except via permitted features.
• Bypass authentication, rate limits, or paywalls.
• Use the Service for unlawful discrimination, harassment, or patient profiling.
• Introduce malware or attempt unauthorised access.
• Misrepresent affiliation with NHS bodies or PharmAnalyser.
• Use automated access that materially degrades the Service for others.

We combine datasets from NHS bodies, UK administrations, regulators, open-government programmes, and other sources. Licences vary; not all NHS-related data is under the Open Government Licence (OGL).

17.1 Our use of Source data

We obtain and use Source data under licences or permissions applicable to us. We present Source data and Derived output through the Service and Reports subject to these Terms.

17.2 Open Government Licence

Where information is made available under the OGL, you may have separate rights to reuse that information under the OGL itself. If you reuse OGL information outside the Service (for example in a permitted Report extract), you must meet the OGL attribution requirements that apply to your reuse.

17.3 Other publisher terms

Where Source data is not OGL, publisher terms may restrict copying, redistribution, or commercial use. We do not grant you rights beyond what those terms and these Terms allow. We will not impose restrictions on you that we have not brought to your attention in these Terms, the product, or the Report itself where practicable.

17.4 PharmAnalyser Content

Layouts, scoring methods, peer groups, narrative templates, and compilations are our Content or licensors’ content. You may not copy or reverse engineer them except as allowed in section 14 and your plan.

17.5 No official endorsement

We are independent. Display of ODS codes, geography labels, or metrics does not imply NHS or regulator endorsement.

Source data is third-party information. We do not guarantee that any Source dataset is accurate, complete, current, or free from error.

18.1 Publisher errors and revisions

Publishers may correct, restate, or withdraw data. Historical files may contain errors discovered later. We reflect updates on our refresh cycle, not necessarily in real time.

18.2 Timeliness and gaps

Publication lag, missing months or quarters, partial national coverage, and definitional changes between periods are common. A missing value may mean not published, suppressed, not applicable, or not yet available—not zero.

18.3 UK nation differences

England, Scotland, Wales, and Northern Ireland use different datasets and definitions. Cross-nation comparisons may be misleading unless the product explicitly supports them.

18.4 Identifiers and organisation history

Contractor codes, ODS statuses, mergers, rebrands, and location changes may not be reflected immediately. Duplicate or ambiguous records may exist upstream.

18.5 Our responsibilities

We use reasonable skill and care in ingesting and presenting Source data. Publisher errors do not remove our duties to you under contract and mandatory law for our own acts and omissions, including mis-processing or mis-description attributable to us (see section 27).

Derived output includes joins, geocodes, peer groups, ranks, percentiles, estimates, similarity scores, and visualisations. Derived output is not Source data and may differ from official statistics.

19.1 Matching and entity resolution

We link organisations using codes, names, addresses, and matching rules. Links may be wrong or incomplete. Inferred group or ownership relationships may be incorrect.

19.2 Estimates and benchmarks

Estimates, benchmarks, and comparative metrics (including gap-style or share-style figures) are model outputs, not bank-verified revenue or cash flow.

19.3 Rankings and leaderboards

Ranks depend on filters, active-status rules, and available fields. A rank change may reflect data revisions or rule updates, not real-world performance alone.

19.4 Combining datasets

Joining datasets can amplify errors. We may show coverage or integrity notices where known limitations exist.

Much of the Service is tables and charts produced by defined rules from Source data and Derived output. Reports are not necessarily generated end-to-end by a single generative large language model. Some Report sections use template-based or rules-based narrative; other features may use automated or AI-assisted text. Where we use AI-assisted text in the product, we aim to label it clearly.

20.1 Methodology

Treat each section according to how it is described in the product or Report. Automated text may not reflect every nuance in the underlying tables.

20.2 Limitations

Automated or AI-assisted text may omit context, misstate relationships, or disagree with underlying figures. Verify material statements against Source fields and Derived output.

20.3 Quality assurance

We do not manually verify every figure or sentence before display. Automated checks do not guarantee accuracy.

Local Search Intelligence (LSI) shows observations about public web and local-search visibility for pharmacies and related competitive context. It is not prescription volume, footfall, or NHS activity data.

21.1 What LSI includes

LSI may show business profile signals, results for selected local search queries, competitor listings for those queries, and information from public web sources. Coverage varies; some locations may not yet have enrichment.

21.2 Rankings and queries

Search positions depend on query wording, device, location, time, and search provider algorithms. Observed positions are snapshots, not guarantees of future visibility or ranking. A completed search may show that your pharmacy was observed in results but not in a particular rank band; that is still a completed search with a usable observation, not the same as a search that produces no usable observation at all.

21.3 On-demand searches and monthly allowance

Where your plan includes on-demand LSI, fresh searches you request consume monthly allowance units when queued, in line with the limits shown in the product. Cached or reused observations within published freshness windows follow the reuse rules shown in the product and do not consume fresh allowance again.

When a fresh on-demand search completes with a usable observation, the allowance consumed for that search is not credited back. When a fresh search finishes without any usable observation—including empty local results after provider execution, or provider timeout or error after we attempted execution—we credit the consumed fresh allowance back to your account for that search under our standard on-demand settlement policy. We do not credit allowance for successful observations merely because your pharmacy was not ranked as you hoped.

Results may differ between runs. Third-party rate limits or outages may delay, fail, or limit results; failures that qualify under the credit policy above are settled as described, not left to discretionary “may credit” treatment.

21.4 Entity matching

Business names and locations in search results may refer to the wrong entity or duplicate listings. Corroborate material findings before relying on them.

21.5 No clinical or dispensing inference

Do not treat LSI as measuring patient visits, prescription flows, or clinical market share.

The Service and Reports are designed to support professional and commercial analysis of organisation-level data. You remain responsible for your decisions and for compliance with duties owed to your clients and regulators.

22.1 Intended use

You may use the Service and permitted Report extracts in due diligence, advisory work, internal strategy, and similar business purposes, together with independent verification and professional advice where appropriate.

22.2 Sole reliance

Do not treat the Service or a Report as the only source of evidence for lending, valuation, investment, acquisition, regulatory submissions, or pricing. Material decisions should be supported by primary records and qualified advisers.

22.3 Regulated advice

We do not provide regulated legal, financial, medical, or pharmacy practice advice.

We aim for reliable operation but do not guarantee uninterrupted access.

23.1 Maintenance and delays

Downtime may result from maintenance, data refresh, publisher delays, third-party services (including search providers), or infrastructure failures.

23.2 Force majeure

Neither party is liable for failure or delay caused by events beyond reasonable control (including natural disasters, war, terrorism, labour disputes, utility failures, and government action), except payment obligations accrued before the event.

23.3 Enterprise

Any uptime or support commitments for Enterprise customers are in the Enterprise agreement.

Our Privacy Policy describes how we process personal data (including cookies and analytics). It is not incorporated as a whole into these Terms as a separate contract for Service features, but both documents apply alongside each other where relevant.

24.1 Processors and publishers

References to subprocessors and service providers in the Privacy Policy relate to personal data processing. Third-party data publishers are not ‘subprocessors’ merely because we use their datasets.

24.2 Enterprise processing

Enterprise data processing terms are in the Enterprise agreement where applicable.

Each party may receive non-public information from the other in connection with the Service. You must use reasonable care to protect our non-public product, pricing, roadmap, and security information we disclose to you. We will use reasonable care to protect your non-public Account details and commercial information you provide, in accordance with the Privacy Policy and applicable law.

25.1 Your commercial information

Watchlists, notes, and Reports you create may contain sensitive commercial information about your business or clients. You decide what to enter and who may access share links (see section 14.3).

25.2 Enterprise

Confidentiality undertakings for Enterprise workspaces may be set out in the Enterprise agreement where they go beyond this section.

You may close your Account via settings or support@pharmanalyser.co.uk, subject to outstanding fees.

26.1 Cancellation vs termination

Cancelling a subscription stops renewal; it is not always the same as closing your Account. Closing your Account ends access subject to retention described in the Privacy Policy and section 13.11.

26.2 Our rights

We may suspend or terminate access for breach, non-payment, risk, or legal or licence requirements, with notice where reasonable.

26.3 Effect on Reports

After termination, stored Reports and share links may become unavailable according to retention settings. We are not obliged to retain Reports indefinitely.

26.4 Survival

Provisions that by nature should continue (fees owed, intellectual property, acceptable use, confidentiality, liability, indemnities, governing law, and dispute resolution) survive termination.

Nothing in these Terms excludes or limits liability that cannot be excluded or limited under applicable law (including for death or personal injury caused by negligence, fraud, or fraudulent misrepresentation).

27.1 Basis of supply

Except as stated in an Enterprise agreement, the Service and Reports are supplied on an ‘as is’ and ‘as available’ basis to the fullest extent permitted by law. This does not affect your mandatory statutory rights as a consumer.

27.2 Source data errors

We are not liable for loss that arises only from errors, omissions, or delays in Source data published by third parties, if we did not cause that loss by our breach of these Terms, negligence, or mis-processing. This clause does not increase our liability and must be read together with the rest of this section.

27.3 Business users — excluded losses

If you are not a consumer, we shall not be liable for loss of profits, loss of business, loss of goodwill, loss of anticipated savings, or indirect or consequential loss arising from use of the Service or Reports.

27.4 How we count claims and the twelve-month period

In this section, a claim means any claim, demand, or cause of action under or relating to these Terms. Related events or a series of connected events arising from the same underlying facts count as one claim for cap purposes.

For the subscription cap in section 27.5, the twelve-month period means the twelve calendar months ending on the date the event giving rise to the claim first occurred. Fees counted are subscription fees actually paid to us for the main-app Service in that period (excluding Enterprise and separately itemised Report fees).

27.5 Cap — paid subscriptions

If you are not a consumer and you have a paid main-app subscription (excluding Enterprise), our total aggregate liability for claims relating to the Service (excluding separately purchased Reports covered by section 27.6) is limited to those subscription fees in the twelve-month period above.

27.6 Cap — Reports

Our total aggregate liability for claims relating to a separately purchased Report is limited to the fee you paid for that Report. Multiple Reports give rise to separate caps for claims relating to each Report. Report fees are not counted again in the subscription cap in section 27.5.

27.7 Free access and Report purchases

Section 27.5 does not apply to Free access because no subscription fees are paid. If you are not a consumer, our aggregate liability for claims relating solely to Free access to the Service (not including separately purchased Reports) is limited to the fees you paid us for that Free access in the twelve-month period in section 27.4 (typically none). Separately purchased Reports while on Free access are subject to section 27.6. Nothing in this section limits non-excludable liability or mandatory consumer remedies.

27.8 Overlapping subscription and Report claims

If a single claim or related series of events could be said to relate to both the Service and a separately purchased Report, we apply only one cap—the higher of the applicable subscription cap in section 27.5 and the Report cap in section 27.6 for that event—not both cumulatively.

27.9 Consumers

If you are a consumer, the CRA and other mandatory rules may give you remedies beyond the limitations in this section. Nothing here affects those rights.

27.10 Enterprise

Enterprise liability is governed by the Enterprise agreement where applicable.

27.11 Protected personnel

Any limitation, exclusion, or indemnity benefit expressed to apply to us is intended to benefit our directors, officers, employees, and contractors who would otherwise be liable for acts or omissions in delivering the Service, only to the extent section 31.6 allows them to rely on it.

This section applies only if you are an organisation or business user acting in trade, business, craft, or profession. It does not apply to consumers.

28.1 Scope

You will indemnify us against reasonable losses, damages, and costs awarded against us or agreed in settlement of a third-party claim arising from: (a) your unlawful redistribution or commercial publication of Reports or bulk extracts contrary to section 14; (b) your infringement of third-party intellectual property through User content you supply; (c) your breach of data protection law in connection with personal data you control; or (d) your scraping or misuse of data contrary to section 16—except to the extent the claim is caused by our negligence or wilful misconduct.

28.2 Limits

This indemnity is limited to the matters listed in section 28.1 and does not apply to every breach of contract.

28.3 Procedure

We will give you prompt notice of a claim, allow you to control the defence with counsel reasonably acceptable to us if you acknowledge responsibility, and cooperate at your expense. You may not settle a claim in a way that admits fault by us or imposes non-monetary obligations on us without our written consent.

We may change features, data coverage, or limits. Material adverse changes to paid features will be notified where required by law or contract.

30.1 Editorial changes

Minor clarifications, formatting, or non-material updates may be posted without notice.

30.2 Material changes

Material changes affecting paid subscribers or consumers will be notified by email or in-product message where practicable before the effective date, with an updated version identifier.

30.3 Acceptance

Where permitted by law, continued use after the effective date may constitute acceptance. For material changes, we may require explicit acceptance at login, renewal, or Checkout. Publication on the website alone may not be enough to bind consumers to adverse changes.

30.4 Enterprise

Enterprise workspaces remain governed by the Enterprise agreement for conflicting terms.

31.1 Entire agreement

These Terms, terms shown at purchase, and any applicable Enterprise agreement form the agreement about the Service.

31.2 Assignment

We may assign our rights to a successor in a merger or asset sale. You may not assign without our consent.

31.3 Severability

Invalid provisions do not affect the remainder.

31.4 No waiver

Failure to enforce is not a waiver.

31.5 Notices

We may give notice by email to your Account address or by posting on the Service. You may give legal notice to support@pharmanalyser.co.uk and ResPublica Intelligence LTD (Company Number SC893159), trading as PharmAnalyser at our registered office.

31.6 Third party rights (Scotland)

The Contract (Third Party Rights) (Scotland) Act 2017 applies. Except as stated in section 27.11, these Terms do not give any person who is not a party any right to enforce any term. The parties do not intend that any term be enforceable under section 1(1) of that Act by anyone other than us and you, except that section 27.11 is intended to be enforceable by our Protected Personnel (directors, officers, employees, and contractors) to the extent permitted by that Act.

These Terms are governed by the law of Scotland. Courts in Scotland have jurisdiction, subject to mandatory consumer rules that may allow consumers to bring proceedings in their home jurisdiction.

32.1 Unfair terms

If you are a consumer, the Unfair Contract Terms Act 1977 and consumer protection legislation may limit the effect of certain exclusions. If you are a business, reasonableness under UCTA may apply to limitations.

Questions or complaints about these Terms or the Service: support@pharmanalyser.co.uk. We will acknowledge complaints within a reasonable time and aim to respond substantively promptly.

33.1 Escalation

If you remain dissatisfied, you may refer eligible disputes to approved alternative dispute resolution schemes where applicable. Nothing prevents either party from seeking court relief where permitted.